Lymphoma radiolabeling

Michel, R.B., Ochakovskaya, R., and Mattes, M.J. (2002) Antibody localization to B-cell lymphoma xenografts in immunodeficient mice importance of using residualizing radiolabels. Clin. Cancer Res. 8, 2632-2639. 

Tositumomab (Bexxar) Radiolabeled MoAb to CD20 Refractory low-grade lymphoma Phase II... 

ZevaHn Ibritumomab tiuxetan Biogen Idee Radiolabeled anti-CD20 Non-Hodgkin s lymphoma 2002... 

Bexxar Tositumomab Corixa, Seattle, WA (originally Coulter Pharmaceuticals) and GlaxoSmithKline, Middlesex, England Radiolabeled anti-CD20 Non-Hodgkin s lymphoma 2003... 

Ibritumomab tiuxetan Zevalin Murine IgGltc anti-CD20, radiolabeled Y-90 Relapsed or refractory low-grade, follicular transformed non-Hodgkin s lymphoma 2002 United States... 

Germany). Dialyzed upper phase samples of brain and lymphoma cells with from 30,000 to 50,000 cpm were used for each TLC plate. All radiolabeled samples were chromatographed in parellel with mouse brain ganglioside standards extracted as described above. 

A two dimensional TI/ system was developed to attempt the purification of Thy-1 glycolipid using only one plate. The radiolabeled glycolipid material (brain or lymphoma) was spotted in a small area in the corner of the plate. The plate was developed twice in one dimension in solvent 1 (C M W, 50 40 9, 0.02% CaCl2) and once in solvent 2 (C M W, NH4OH, 60 35 6 14) in the second dimension. Each plate was air dried for one hour then dried in vacuo for 45 minutes (between runs) to ensure dryness. 

Radiolabeling and the Analysis of Thy-1 Active Glycolipids. The amount of Thy-1 active glycolipids in brain, thymocytes or lymphoma cells was found to be extremely small and could only be detected by immunological methods and not by chemical means. 

Press, O.W. Eary, J.F. Appelbaum, F.R. Martin, P.J. Badger, C.C. Nelp, W.B. Glenn, S. Butchko, G. Fisher, D. Porter, B. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. New Engl. J. Med. 1993, 329, 1219-1224. 

Press, O.W. Radiolabeled antibody therapy of B-cell lymphomas. Semina. Oncol. 1999, 26 (5 Suppl 14), 58-65. 

B., Kidd, P., Thomas, E. D., and Bernstein, I. D. (1989) Treatment of refractory non-Hodgkin s lymphoma with radiolabeled MB -1 (anti-CD37) antibody. J. Clin. Oncol. 7, 1027-1038. 

The use of radiopharmaceuticals for therapeutic apphcations a- or )8 -emitters) is increasing. The first EDA-approved radiopharmaceutical in the United States was, in fact, for therapeutic use. Sodium iodide was approved in 1951 for treating thyroid patients. There are currently FDA-approved radiopharmaceuticals for alleviating pain in patients whose cancer has metastasized to their bones. These include sodium P-phosphate, Sr-chloride, and Sm-EDTMP (where EDTMP stands for ethylenedi-aminetetramethylphosphate). In February 2002 the first radiolabeled monoclonal antibody was approved by the FDA for the radioimmxmotherapy treatment of cancer. Yttrium-90-labeled anti-CD20 monoclonal antibody is used to treat patients with non-Hodgkin s lymphoma. 

Stopar T G, Milinaric-Rascan I, Fettich J, et al. (2006). Tc-rituximab radiolabelled by photoactivation a new non-Hodgkin s lymphoma imaging agent. Eur. J. Nucl. Med. Mol. Imaging. 33 53-59. 

---